Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2026 08:00 ET | Source: SOTIO Biotech B.V.

SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma

SOTIO announces the U.S. FDA has granted Orphan Drug Designation (ODD) for the treatment of osteosarcoma to SOT106, the Company's investigational ADC.